NVCR EBITDA
-$132.65MTTM · USD
Period ending:
NVCR FY EBITDAUSD
$44.83M-$177.45M
2013-12-312025-12-31
Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.
NVCR ebitda history
Earnings before interest, taxes, depreciation, and amortization. The available annual fiscal periods series contains 13 observations from Dec 31, 2013 to Dec 31, 2025.
| Period ending | EBITDA (USD) |
|---|---|
| -121,600,000 | |
| -109,584,000 | |
| -177,452,000 | |
| -67,888,000 | |
| -38,384,000 | |
| 44,834,000 | |
| 13,510,000 | |
| -23,445,000 | |
| -29,127,000 | |
| -108,890,000 | |
| -101,115,000 | |
| -78,193,000 | |
| -63,133,000 |
Compare ebitda
Other companies in Health Care. Each page shows its own reporting periods and currency.
- Guardant Health Inc (GH) ebitda
- Bridgebio Pharma Inc (BBIO) ebitda
- Brightspring Health Services Inc (BTSG) ebitda
- Madrigal Pharmaceuticals Inc (MDGL) ebitda
- Ensign Group Inc (ENSG) ebitda
- Glaukos Corp (GKOS) ebitda
- Vaxcyte Inc (PCVX) ebitda
- Krystal Biotech Inc (KRYS) ebitda
All NVCR financial metrics · NVCR stock overview · How to interpret financial metrics
